Literature DB >> 26036268

Role of the 340B Drug Discount Program in Recent Cancer Care Trends.

Hagop M Kantarjian1, Robert Chapman2.   

Abstract

The 340B program, a drug discount program created by the US Congress, allows safety-net providers to access discounted drug pricing that helps low-income and vulnerable patients. This program has recently been the subject of significant discussions as to its potential implications. Herein we review the role of the 340B drug discount program and its relevance to recent trends in cancer care and to the access of safety-net providers and vulnerable patients to much-needed drug support.
Copyright © 2015 by American Society of Clinical Oncology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26036268     DOI: 10.1200/JOP.2014.002139

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN: 1554-7477            Impact factor:   3.840


  1 in total

1.  Economic Evaluation of Changes in Reimbursement for Medications Purchased Through the 340B Drug Pricing Program.

Authors:  Lauren A Endriukaitis; Genevieve L Hayes; Jason Mills
Journal:  Hosp Pharm       Date:  2019-11-20
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.